Cue Biopharma, Inc. (CUE)
- Previous Close
1.4100 - Open
1.4000 - Bid 1.3500 x 100
- Ask 1.4000 x 100
- Day's Range
1.3150 - 1.4400 - 52 Week Range
1.3030 - 5.1200 - Volume
261,676 - Avg. Volume
261,312 - Market Cap (intraday)
66.398M - Beta (5Y Monthly) 2.01
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1100 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.40
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
www.cuebiopharma.comRecent News: CUE
Performance Overview: CUE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CUE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CUE
Valuation Measures
Market Cap
66.40M
Enterprise Value
32.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.38
Price/Book (mrq)
1.79
Enterprise Value/Revenue
5.93
Enterprise Value/EBITDA
-0.71
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.53%
Return on Equity (ttm)
-98.73%
Revenue (ttm)
5.49M
Net Income Avi to Common (ttm)
-50.73M
Diluted EPS (ttm)
-1.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
48.51M
Total Debt/Equity (mrq)
39.63%
Levered Free Cash Flow (ttm)
-20.2M